ESOC 2024 – presentation

We are thrilled to announce that Lys Therapeutics will be a presenting company at the 10th European Stroke Organisation Conference (ESOC 2024), taking place from 15–17 May in Basel, Switzerland. This prestigious event brings together leading experts and innovators in stroke research and treatment from around the world.

Our very own Dr. Manuel BLANC, CEO and co-founder, along with Dr. Jean-Baptiste BERTRAND, Head of Clinical & Non-Clinical Operations, will be representing Lys Therapeutics at the conference. They will be sharing our latest advancements and insights in stroke therapy, highlighting our commitment to transforming the lives of stroke patients through innovative medical solutions, including the development of our lead #antibody LYS241.

We look forward to connecting with fellow researchers, clinicians, and industry professionals at ESOC 2024. Let’s join forces to push the boundaries of stroke treatment and make a lasting impact on patient outcomes.

💡Abstract Title: “Glunomab/LYS241: A Monoclonal Antibody Counteracting Blood-Brain Barrier Leakage Caused By Endogenous tPA And Thrombolytics (rtPA/TNK) After Ischemic Stroke”

🎤 Presenter: Dr. Manuel BLANC, CEO

📅 Date: Wednesday, 15 May 2024

📍 Paper Poster P0191 – Theme Hyperacute Management

See you in Basel! 🇨🇭

#ESOC2024 #Innovation #Biotech #VoiceofStroke #Stroke #HealthcareInnovation #StrokeTreatment #StrokeResearch #MedicalResearch #patients #LysTherapeutics #LYS241 #CNS #NeurovascularDisorders